GONGWIN BIOPHARM CO., LTD
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
PTS - MITTA
The content above was translated by Ai
Founded Year
2014
Unified Business No.
24751115
Status
Active
Number of Employees
0
Total Paid-in
Capital
1,735,978,000 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
OTC listing(2025)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Gongwin Biopharm Holdings, Co., Ltd. Cayman (Gongwin-KY; ticker: 6617), founded in 2014, is a Taiwan-based biopharmaceutical company focused on developing novel anti-cancer drugs.
In 2017, Gongwin-KY was granted the "Biotech New Drug Company" designation by MOEA in Taiwan, and it became a publicly traded company on the Taipei Emerging Stock Board.
Gongwin-KY utilizes a proprietary technology called MITTA (minimally-invasive targeted tumor ablation) therapy for the treatment of focal malignancies. This innovative tumor ablation technique involves the intratumoral injection of our API, PTS (para-toluene sulfonamide), which is administered using existing diagnostic and minimally-invasive intervention techniques. This approach is unique and distinct in the current market for treating focal malignancies.
Our product, PTS 302, has been newly listed in the pharmacopeia of China and has received marketing approval from NMPA (China) for the treatment of severe malignant airway obstructions in non-small cell lung cancers (NSCLC). We are proud to report that PTS 302 has demonstrated both safety and efficacy in treating tumors causing airway obstructions, and we are confident in our ability to introduce this novel therapeutic approach as a superior treatment for focal malignancies in the airways.
PTS intratumoral injections have high selectivity for cancer cells and have minimum damage to healthy cells. It has shown great results in treating tumors in H & N cancers, liver cancer, breast cancer, and other types. These trials are currently running in Taiwan, China, and the USA.
Gongwin Biopharm is also utilizing its core technology to develop tumor ablation formulas for companion animals in Taiwan. The company has completed a pre-field study to evaluate potential indications to target and has started field trials for treating canine melanomas in 2022. We are one of the few biopharmaceutical companies in the world developing tumor-ablating techniques for both humans and companion animals.
In 2017, Gongwin-KY was granted the "Biotech New Drug Company" designation by MOEA in Taiwan, and it became a publicly traded company on the Taipei Emerging Stock Board.
Gongwin-KY utilizes a proprietary technology called MITTA (minimally-invasive targeted tumor ablation) therapy for the treatment of focal malignancies. This innovative tumor ablation technique involves the intratumoral injection of our API, PTS (para-toluene sulfonamide), which is administered using existing diagnostic and minimally-invasive intervention techniques. This approach is unique and distinct in the current market for treating focal malignancies.
Our product, PTS 302, has been newly listed in the pharmacopeia of China and has received marketing approval from NMPA (China) for the treatment of severe malignant airway obstructions in non-small cell lung cancers (NSCLC). We are proud to report that PTS 302 has demonstrated both safety and efficacy in treating tumors causing airway obstructions, and we are confident in our ability to introduce this novel therapeutic approach as a superior treatment for focal malignancies in the airways.
PTS intratumoral injections have high selectivity for cancer cells and have minimum damage to healthy cells. It has shown great results in treating tumors in H & N cancers, liver cancer, breast cancer, and other types. These trials are currently running in Taiwan, China, and the USA.
Gongwin Biopharm is also utilizing its core technology to develop tumor ablation formulas for companion animals in Taiwan. The company has completed a pre-field study to evaluate potential indications to target and has started field trials for treating canine melanomas in 2022. We are one of the few biopharmaceutical companies in the world developing tumor-ablating techniques for both humans and companion animals.
The content above was translated by Ai
